002653.SZ Haisco Pharmaceutical Group Co., Ltd. Loading... : Investor Sentiment and Bull/Bear Views

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
All Content
Source feeds
Buzzberg Top 50
All market capsNo capitalization filter
200 B and aboveMega
10 B to 200 BLarge
2 B to 10 BMid
0 to 2 BSmall
Custom
Enter market cap range in B USD
All directions
▲ Long
▼ Short
⛔ Avoid
✂ Close
◦ Others
Any score
LOW+
MED+
HIGH
? ?
05:09
Jan 12
Lency Gu Head of Business Development, Haisco Pharmaceutical Group Bloomberg Markets
Haisco licensing validates innovative pipeline.
Haisco's license collaboration with Air & Access/Nexus validates its China-generated data and innovation. It receives over $100 million upfront, up to $1 billion total plus equity, royalties and sublicense income, and a 19.9% NewCo stake. With 48 programs, about 30 active pipeline assets, and a partnership-led overseas strategy, multiple assets can drive global expansion despite domestic pricing pressure.
HIGH

About 002653.SZ Investor Commentary

Across the available history and selected sources, Buzzberg tracks 002653.SZ (Haisco Pharmaceutical Group Co., Ltd.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Lency Gu.